Jun Tohyama

Dr. Jun Tohyama


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2015 in Hepatology Research
Verified
Journal Article
Closed access
PDF file
SMShiro Miyayama
Shiro Miyayama
MYMasashi Yamashiro
Masashi Yamashiro
KNKeiichi Nagai
Keiichi Nagai
JTJun Tohyama
Jun Tohyama
KKKenshi Kawamura
Kenshi Kawamura
NSNaoko Sakuragawa
Naoko Sakuragawa

1 March 2021 in Epilepsy & Behavior
Verified
Journal Article
Open access
NHNaoya Hasegawa
Naoya Hasegawa
JTJun Tohyama
Jun Tohyama
The present study evaluated whether patients with epilepsy who received both levetiracetam (LEV) and perampanel (PER) therapy showed side effects of irritability. The study also examined the relationship between patient characteristics and irritability when it occurred as a side effect. We retrospectively examined medical records of 98 patients with epilepsy who were treated with both LEV and PER at the Department of Psychiatry in the Epilepsy Center of Nishiniigata Chuo National Hospital in Japan. We performed multiple regression analyses with the presence/absence of irritability due to LEV or PER as the dependent variables and clinical characteristics of the patients as independent variables. LEV and PER caused irritability in 7 and 17 of 98 patients, respectively. LEV- and PER-related irritability did not occur in the same patients. A logistic multiple regression analysis revealed that EEG findings of temporal focal epileptic discharge were significantly associated with increased incidence of irritability due to LEV. LEV-related irritability decreased significantly with higher dosages of LEV. Another logistic multiple regression analysis revealed that a psychiatric comorbidity of irritability and EEG findings of nontemporal focal epileptic discharge were significantly associated with increased incidence of irritability due to PER. LEV and PER cause irritability in different patient groups. Additionally, irritability as a side effect was present only at low dosages of LEV, but PER tended to cause irritability even at high dosages.


28 April 2022 in Epilepsia Open
Verified
Journal Article
Open access
TKTakao Komatsubara
Takao Komatsubara
YKYu Kobayashi
Yu Kobayashi
AHAkiko Hiraiwa
Akiko Hiraiwa
SMShinichi Magara
Shinichi Magara
MHMoemi Hojo
Moemi Hojo
JTJun Tohyama
Jun Tohyama
Objective: This study aimed to identify the recurrence rate of genetic generalized epilepsy (GGE) and risk factors for recurrence after antiseizure medication (ASM) withdrawal in adolescent patients.Methods: We retrospectively reviewed medical records of patients with GGE who were included in the registry at the Department of Child Neurology, National Hospital Organization Nishiniigata Chuo Hospital from 2000 through 2020. The eligibility criteria were as follows: onset of epileptic seizures at <15 years of age, treatment with an ASM, and attempted treatment withdrawal at 10‐19 years of age. The rates of seizure recurrence after drug withdrawal were evaluated. Moreover, several variables were evaluated as predictors of recurrence.Results: In total, 77 patients with GGE (21, 13, and 43 patients with juvenile myoclonic epilepsy [JME], juvenile absence epilepsy [JAE], and epilepsy with generalized tonic–clonic seizures alone [EGTCSA], respectively) were included in this study. Recurrence was detected in 68% of patients with GGE (86%, 31%, and 70% of patients with JME, JAE, and EGTCSA, respectively). Recurrence rates for patients who developed epilepsy at ≥13 years of age, those who started dose reduction at ≥16 years of age, those who exhibited a seizure‐free period of <36 months before withdrawal, and those who chose to discontinue treatment at their own discretion were significantly higher than those for their counterparts. Multivariate analysis revealed that initiation of dose reduction at ≥16 years of age was associated with increased recurrence risk. Meanwhile, a diagnosis of JAE was associated with decreased recurrence risk. All patients with JAE were treated with valproic acid.Significance: Antiseizure medication withdrawal at ≥16 years of age and a diagnosis other than JAE may be independent risk factors for seizure recurrence after drug withdrawal in adolescent patients.

1 December 2008 in Journal of Neuroimmunology
Verified
Journal Article
Closed access
TMTakeshi Matsushige
Takeshi Matsushige
TITakashi Ichiyama
Takashi Ichiyama
BABanu Anlar
Banu Anlar
JTJun Tohyama
Jun Tohyama
KNKeiko Nomura
Keiko Nomura
SFSusumu Furukawa
Susumu Furukawa

1 March 2021 in Brain and Development
Verified
Journal Article
Closed access
AHAkiko Hiraiwa
Akiko Hiraiwa
KMKou Matsui
Kou Matsui
YNYumi Nakayama
Yumi Nakayama
TKTakao Komatsubara
Takao Komatsubara
SMShinichi Magara
Shinichi Magara
JTJun Tohyama
Jun Tohyama